Miltiadis Leon, MD
Interventional Cardiology · San Angelo, TXNPI 1558328690
Payments from drug & device makers
Across 468 payments — averaging $87.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Abbott$6K
- Penumbra, Inc.$6K
- Bard Peripheral Vascular, Inc.$5K
- Philips North America LLC$4K
- Veryan Medical Incorporated$3K
- plus $10K from 29 others
What the payments were for
- Speaking & faculty fees$4,50011%
- Travel & lodging$11,43028%
- Food & beverage$24,63160%
- Education$2761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 110 | $6,909 |
| Abbott | 57 | $5,910 |
| Penumbra, Inc. | 26 | $5,623 |
| Bard Peripheral Vascular, Inc. | 7 | $4,991 |
| Philips North America LLC | 51 | $3,961 |
| Veryan Medical Incorporated | 48 | $3,335 |
| Cardiva Medical, Inc. | 33 | $3,067 |
| Cardiovascular Systems Inc. | 18 | $2,317 |
| Impulse Dynamics (USA) Inc. | 9 | $631 |
| Bolton Medical Inc | 5 | $504 |
| Cardinal Health 200 LLC | 8 | $461 |
| Biotronik Inc. | 9 | $358 |
| Angiodynamics, Inc. | 4 | $329 |
| Celonova Biosciences, Inc. | 2 | $311 |
| AstraZeneca | 11 | $233 |
| Edwards Lifesciences | 2 | $217 |
| E.r. Squibb & Sons, L.L.C. | 24 | $205 |
| Teleflex LLC | 4 | $199 |
| Imperative Care, Inc | 3 | $193 |
| Cordis US CORP. | 5 | $182 |
| Siemens Medical Solutions USA, Inc. | 1 | $126 |
| Johnson & Johnson | 8 | $125 |
| Tactile Systems Technology Inc | 2 | $99 |
| Abiomed | 1 | $99 |
| Boston Scientific | 4 | $86 |
| Chiesi USA, Inc. | 1 | $80 |
| Amarin Pharma, Inc. | 3 | $53 |
| Reflow Medical Inc | 3 | $44 |
| Novartis | 2 | $44 |
| Merck | 2 | $33 |
| Amgen | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Bardy Diagnostics, Inc. | 1 | $26 |
| Cook Medical LLC | 1 | $16 |
| Shockwave Medical, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,995
- LUTONIX$4,658
- Allure CRT Pacemaker$1,944
- Peripheral Orbital Atherectomy System$1,476
- IGT D Peripheral$1,474
- Xience V coronary stent system$1,321
- HawkOne$1,267
- Cardiva VASCADE 6/7F VCS$1,035
- BioMimics 3D Vascular Stent System$925
- Vascular Closure Device$738
- Omnilink Elite vascular stent system$698
- OPTIMIZER$444
- Diamondback Peripheral$425
- BioMimics$385
- Xience Sierra Coronary Stent System$323
- Assurity Pacemaker$300
- Cardiva VASCADE MVP VVCS 6-12F$233
- RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM$150
- SpiderFX$130
- GLIDESHEATH SLENDER$130
How this compares
$40,837 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $140,825 |
| XareltoRivaroxaban | 99 | $83,988 |
| EntrestoSacubitril/Valsartan | 58 | $52,124 |
| BrilintaTicagrelor | 27 | $15,472 |
| JardianceEmpagliflozin | 21 | $13,042 |
| Cilostazol | 230 | $4,077 |
| ClopidogrelClopidogrel Bisulfate | 307 | $3,400 |
| Metoprolol Succinate | 306 | $3,301 |
| Potassium Chloride | 146 | $1,906 |
| Ranolazine ErRanolazine | 15 | $1,674 |
| Rosuvastatin Calcium | 104 | $1,148 |
| Atorvastatin Calcium | 156 | $1,099 |
| Ezetimibe | 56 | $1,061 |
| Losartan Potassium | 150 | $998 |
| Nebivolol Hcl | 18 | $985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $125 | $83,98899 claims |
| NovartisEntresto | $44 | $52,12458 claims |
| AstraZenecaBrilinta | $233 | $15,47227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Angelo
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.